NGF and neuropathy: On the other hand, regarding targeting, by simulating the neuropathy condition in vitro, specifically inflammation and oxidative stress leading to an imbalance in ion transport, the data revealed that the investigational substances at all dosages tested seem to be able to repair the damage to the myelin sheath that protects the axon and simultaneously act on NGF release and bind to the neurotrophin p75 receptor, reproducing the mechanism of analgesia observed in humans.